Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:
Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China’s domestic market
- CanSino Biologics jumped 59 per cent in debut trading in Hong Kong on Thursday, reflecting the best first day trading gain in the city since 2017
- Steve Chao, chief operating officer, says the company has 15 vaccines under development
Topic |
IPO
Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo: